# US 10,501,812 B2 · Compositions, kits and related methods for the detection and/or monitoring of Listeria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,501,812 B2
- Document ID: US10501812B2
- Status: Granted
- Kind: B2
- Application number: 15/424,052
- Filed: 2017-02-03
- Published: 2017-07-27
- Granted: 2019-12-10
- Earliest claimed: 2008-12-30
- Assignees: Gen-Probe Incorporated
- Applicants: Gen-Probe Incorporated
- Inventors: Michael R. Reshatoff; Kristin W. Livezey; James J. Hogan
- Web page: https://patentgrep.com/patent/US10501812B2

## CPC

- C12Q 1/689: for bacteria
- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- C12Q 1/6865: Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided are compositions, kits, and methods for the identification of Listeria. In certain aspects and embodiments, the compositions, kits, and methods may provide improvements in relation to specificity, sensitivity, and speed of detection.

## Claims

### Claim 1

A method for detecting Listeria in a sample, the method comprising:
performing a nucleic acid amplification assay using a set of oligonucleotides comprising a T7 provider oligonucleotide and a primer oligonucleotide, wherein the T7 provider oligonucleotide and the primer oligonucleotide target sequences in a region of Listeria nucleic acid corresponding to nucleotides 1180-1370 of the 16S rRNA of E. coli, represented by SEQ ID NO:113, and wherein the T7 provider oligonucleotide and the primer oligonucleotide used in said amplification assay target opposite strands of the Listeria nucleic acid sequence to be amplified, and
detecting the presence or absence of amplification product, wherein the presence of the amplification product indicates the presence of Listeria in the sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the detecting step utilizes a detection oligonucleotide that specifically hybridizes to the amplification product.

### Claim 3 (depends on 2)

The method of claim 2, wherein the detection oligonucleotide is a molecular torch.

### Claim 4 (depends on 3)

The method of claim 3, wherein
the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:55,
the primer oligonucleotide has a sequence consisting of SEQ ID NO:65, and
the molecular torch has a sequence consisting of SEQ ID NO:72, SEQ ID NO:77, SEQ ID NO:78, or SEQ ID NO:79.

### Claim 5 (depends on 4)

The method of claim 4, wherein the molecular torch has the sequence consisting of SEQ ID NO:72.

### Claim 6 (depends on 4)

The method of claim 4, wherein the molecular torch has the sequence consisting of SEQ ID NO:77.

### Claim 7 (depends on 4)

The method of claim 4, wherein the molecular torch has the sequence consisting of SEQ ID NO:78.

### Claim 8 (depends on 4)

The method of claim 4, wherein the molecular torch has the sequence consisting of SEQ ID NO:79.

### Claim 9 (depends on 3)

The method of claim 3, wherein
the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:55,
the primer oligonucleotide has a sequence consisting of SEQ ID NO:64, SEQ ID NO:65, or SEQ ID NO:68, and
the molecular torch has a sequence consisting of SEQ ID NO:78.

### Claim 10 (depends on 9)

The method of claim 9, wherein the primer oligonucleotide has the sequence consisting of SEQ ID NO:64.

### Claim 11 (depends on 9)

The method of claim 9, wherein the primer oligonucleotide has the sequence consisting of SEQ ID NO:68.

### Claim 12 (depends on 3)

The method of claim 3, wherein
the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:57,
the primer oligonucleotide has a sequence consisting of SEQ ID NO:64 or SEQ ID NO:65, and
the molecular torch has a sequence consisting of SEQ ID NO:78.

### Claim 13 (depends on 12)

The method of claim 12, wherein the primer oligonucleotide has the sequence consisting of SEQ ID NO:64.

### Claim 14 (depends on 12)

The method of claim 12, wherein the primer oligonucleotide has the sequence consisting of SEQ ID NO:65.

### Claim 15 (depends on 3)

The method of claim 3, wherein
the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:57,
the primer oligonucleotide has a sequence consisting of SEQ ID NO:64, and
the molecular torch has a sequence consisting of SEQ ID NO:72 or SEQ ID NO:78.

### Claim 16 (depends on 15)

The method of claim 15, wherein the molecular torch oligonucleotide has the sequence consisting of SEQ ID NO:72.

### Claim 17 (depends on 3)

The method of claim 3, wherein
the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:55, or SEQ ID NO:57,
the primer oligonucleotide has a sequence consisting of SEQ ID NO:64, and
the molecular torch has a sequence consisting of SEQ ID NO:78.

### Claim 18 (depends on 17)

The method of claim 17, wherein the T7 provider oligonucleotide has the sequence consisting of SEQ ID NO:49.

### Claim 19 (depends on 17)

The method of claim 17, wherein the T7 provider oligonucleotide has the sequence consisting of SEQ ID NO:50.

### Claim 20 (depends on 3)

The method of claim 3, wherein
the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:47,
the primer oligonucleotide has a sequence consisting of SEQ ID NO:68, and
the molecular torch has a sequence consisting of SEQ ID NO:79.